PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
January 18, 2026Science Immunology

Structural variation tunes apoptotic responses to drive immune escape in melanoma

View Full Paper
Ask AI
Bookmark
Share

Authors

KKKyung Lock KimGGGabriel K. Griffin

Discussion

Loading...

Member takes

Overview

Reveals how structural variations affect apoptosis in melanoma, suggesting mechanisms of immunotherapy resistance.

Key Points

  • The research aims to investigate how structural variations in melanoma influence apoptotic responses and contribute to immunotherapy resistance.
  • Analyzed copy-number variations associated with apoptotic gene dosage.
  • Investigated the relationship between structural variations and immune response in melanoma samples.
  • Assessed immune escape mechanisms linked to apoptosis alterations.
  • Identified specific copy-number variations that enhance apoptosis resistance.
  • Demonstrated that altered apoptotic gene dosage is a significant factor in immunotherapy resistance.
  • Showed a clear correlation between structural variation and immune escape strategies in melanoma.

Cite This Study

Kim et al. (2026) studied this question.

synapsesocial.com/papers/696c772aeb60fb80d1395711https://doi.org/10.1126/sciimmunol.aef3843
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Somatic structural variants drive distinct modes of oncogenesis in melanoma2024 · 1 citations
  2. 2Transposable Elements and Homotypic Niches Drive Immune Dynamics and Resistance in Melanoma Epigenetic-based immunotherapy2025
  3. 3Abstract 6924: Structural variant dynamics in melanoma: Unraveling tumor heterogeneity and evolution2024
  4. 4Abstract LB250: Dynamics of transcript alternations and differential splicing in the evolution of acquired MAPKi resistance in melanoma2024
  5. 5Transposable elements and homotypic niches as drivers of immune dynamics and resistance in melanoma epigenetic-based immunotherapy.2026